Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of Tuesday, October 6, 2026.
RETURN ON ASSETS (ROA)
N/A
Market Cap
$867.60M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$856.30M
Return on Assets (ROA)
-32.46%
TTM Avg
-61.56%
3Y Avg
-55.11%
5Y Avg
-72.90%
Market Cap
$852.55M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$844.28M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$837.43M
Return on Assets (ROA)
-9.67%
TTM Avg
-10.63%
3Y Avg
-19.71%
5Y Avg
-38.52%
Market Cap
$903.13M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
Market Cap
$819.44M
Return on Assets (ROA)
-8.70%
TTM Avg
6.33%
3Y Avg
-16.09%
5Y Avg
-46.82%
Market Cap
$915.95M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -23.15% | -12.59% | -25.36% | -32.38% |
| Jade Biosciences, Inc. (JBIO)vs › | $856.30M | -32.46% | -61.56% | -55.11% | -72.90% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -24.96% | -29.43% | -70.30% | -70.30% |
| Alumis Inc. (ALMS)vs › | $844.28M | -78.30% | -72.68% | -105.45% | -105.45% |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -9.67% | -10.63% | -19.71% | -38.52% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -22.62% | -55.95% | -57.94% | -46.38% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | -8.70% | 6.33% | -16.09% | -46.82% |
| Bioventus Inc. (BVS)vs › | $915.95M | 8.09% | -0.64% | -8.03% | -4.54% |
| InMode Ltd. (INMD)vs › | $812.20M | 10.76% | 17.66% | 20.82% | 23.86% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
